Coronavirus company news summary – COVAXX signs vaccine supply deal with developing countries – Moderna and the European Commission confirm their vaccine supply deal

26 November 2020 (Last Updated November 26th, 2020 08:57)

26 November 2020

Celltrion announced the enrolment completion of 327 patients suffering from mild to moderate Covid-19 symptoms in its global Phase II clinical trial of CT-P59, a monoclonal antibody treatment candidate. Celltrion is considering submitting an emergency use authorisation (EUA) request to the Korean Ministry of Food and Drug Safety (MFDS), after getting positive results from the study.

COVAXX has received advance purchase commitments worth $2.8bn to supply over 140 million doses of its potential Covid-19 vaccine to emerging and developing countries such as Brazil, Ecuador, and Peru. The multitope peptide-based vaccine is currently undergoing trials in Taiwan. COVAXX believes it can produce one billion doses of the vaccine by the end of 2021.

The European Commission has approved the supply of 80 million doses of Moderna‘s mRNA-1273 vaccine candidate to fight Covid-19 . The Commission seeks to fast-track the access of a safe and effective Covid-19 vaccine for Europe and can also double the purchase to 160 million doses, according to the terms of  the agreement.

RedHill Biopharma announced partnerships with two US-based manufacturers to support the large-scale manufacturing of Opaganib for Covid-19. The collaborations advance efforts to submit potential emergency use applications for Opaganib to fight severe Covid-19 pneumonia in early 2021.